Newscast – Page 131 – media

Researchers 3D-Print Patch That Heal Heart After Heart Attack

Heart disease kills more than 360,000 people a year, in the US alone. During a heart attack, a person loses blood flow to the heart muscle, causing cells to die. The heart muscle cells can't be replaced, so the body forms scar tissue, which puts the person at risk for compromised heart function and future heart failure.
- Source: mindsofmalady
- 570
- December 22, 2017
heart attacks Researches
3D-Printed Implant Fuses With Bone To Repair Broken Limbs

Most of us have had a broken bone at some point in our lives and we can all agree that it is not a pleasant feeling. Our skeletal system, though not fragile, is susceptible to an occasional crack or a full-blown broken bone.
- Source: orthofeed
- 869
- December 22, 2017
bone Researches skeletal
Sensor-enhanced surgical robot enables highly precise and safe spinal operations

Researchers from the University of Bern, Inselspital, Bern University Hospital and the Swiss Center for Electronics and Microtechnology develop a high-precision, sensor-based surgical robot for spinal operations together with industry partners. Their project is being funded with two million Swiss francs, sponsored by the "BRIDGE" programme of the Swiss National Science Foundation and the Commission for Technology and Innovation.
- Source: medicalxpress
- 390
- December 22, 2017
Researches robotic surgery spinal
Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek

Tessa Therapeutics, an international clinical stage biopharmaceutical company focusing on T cell therapy for solid tumors, announced the completion of a USD 80 million financing round led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.
- Source: Prnewswire
- 451
- December 22, 2017
cell Market Views tumor
Marital Status and Outcomes in Patients With Cardiovascular Disease

Background Being unmarried is associated with decreased survival in the general population. Whether married, divorced, separated, widowed, or never‐married status affects outcomes in patients with cardiovascular disease has not been well characterized.
- Source: drugdu
- 458
- December 22, 2017
cardiovascular disease Marital Status Researches
What Happens When You Get Pregnant In Your 20s, 30s, 40s

There's no shortage of info (and misinformation) out there about when to get pregnant - or when not to. But no matter what your search engine, great aunt, or the random lady standing next to you in line for coffee says, there's no magical right time. However, there are plenty of factors that may offer a sneak peek into the type of pregnancy you'll have. How old you are? Yep, that's definitely one of them.
- Source: msn
- 436
- December 22, 2017
pregnant Researches
Why Medical Device Cyber Threats Are Surging

Medical devices are increasingly the targets of cyber thieves looking to get their hands on sensitive information. And the risks are growing rapidly.
- Source: forbes
- 663
- December 21, 2017
healthcare Market Views medical device
Edible Battery To Power Internal Medical Devices

Imagine taking a pill with an ingestible sensor that takes measurements and sends information wirelessly to your doctor, or a pill that senses changes in your gut microbiome and adjusts its dose accordingly. Ingestible medical devices promise such applications, and many more, but a big challenge is making their power sources safe for our bodies.
- Source: popsci
- 579
- December 21, 2017
medical device Researches sensor
The Top 3 Digital Health Trends to Watch In 2018

Digital health broke out in 2017. We saw more investment than ever before: Over $4.7 billion flowed into a record number of companies. While these record-breaking investments underscore the enthusiasm for new digital health solutions, another revolution was quietly happening just outside the spotlight.
- Source: fortune
- 625
- December 21, 2017
digital health Researches Telemedicine
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active Psoriatic Arthritis

XELJANZ/XELJANZ XR, THE FIRST ORAL JAK INHIBITOR IN THE U.S. FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS, IS NOW APPROVED FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
- Source: Pfizer
- 535
- December 21, 2017
DMARDs New Approvals rheumatoid arthritis XELJANZ

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.